Last reviewed · How we verify
CD70-targeted CAR-T cells
At a glance
| Generic name | CD70-targeted CAR-T cells |
|---|---|
| Sponsor | Chongqing Precision Biotech Co., Ltd |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN） (PHASE1)
- CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors (PHASE1)
- CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms (EARLY_PHASE1)
- A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease (PHASE1)
- Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE (PHASE1)
- Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) (PHASE1)
- CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors (PHASE1)
- Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CD70-targeted CAR-T cells CI brief — competitive landscape report
- CD70-targeted CAR-T cells updates RSS · CI watch RSS
- Chongqing Precision Biotech Co., Ltd portfolio CI